What Makes a Medtech Company Investable? Interview with Neuros Medical CEO David Veino

Neuros Medical’s Altius system addresses the significant unmet need of chronic post-amputation pain, a condition affecting 80% of the 2.5 million lower-limb amputees in the United States. By utilizing an on-demand, high-frequency nerve block, the device offers a non-opioid alternative for patients who have often failed multiple prior therapies. Commercial strategy centers on mapping the patient journey upstream, shifting focus from traditional neurosurgeons to vascular surgeons and prosthetists who serve as primary referral sources. Securing a Category 1 CPT code required rigorous, active sham-controlled clinical trials that demonstrated statistically significant pain reduction and improved quality of life. Scaling such novel medical technology demands a clear, succinct investor narrative, a deep understanding of reimbursement pathways, and the flexibility to adapt clinical and commercial strategies based on direct, honest feedback from stakeholders.